Enter your terms above and click the 'Search' button.

Showing articles 0 to 8 of 8 Filter Applied: alemtuzumab (Click to remove) Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis Neurol 102:e208006, Ng, HS.,et al, 2024 Alemtuzumab CARE-MS I 5-year follow-up Neurol 89:1107-1116, Havrdova, E.,et al, 2017 Alemtuzumab CARE-MS II 5-year follow-up Neurol 89:1117-1126, Coles, A.J.,et al, 2017 Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis JAMA Neurol 73:757-759, Penkert, H.,et al, 2016 Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS Neurol 87:1464-1472, Arnold, D.L.,et al, 2016 Alemtuzumab for Multiples Sclerosis: Who and When to treat? Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012 Monoclonal Antibody Therapies and Neurologic Disorders Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008 Emerging Monoclonal Antibody Therapies for Multiple Sclerosis Neurologist 12:171-178, Cree,B., 2006 Showing articles 0 to 8 of 8